Date: 2017-08-03
Type of information: Termination of an agreement
Compound: fully human therapeutic antibodies
Company: Regeneron Pharmaceuticals (USA - NY) Sanofi (France)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases
Type agreement: development - commercialisation
Action mechanism: monoclonal antibody
Disease:
Details:
- • On August 3, 2017, Regeneron Pharmaceuticals announced that its Antibody Discovery Agreement with Sanofi will end on December 31, 2017 without any extension. Praluent® (alirocumab), Dupixent® (dupilumab), Kevzara® (sarilumab), REGN2810 (anti-PD-1), REGN3500 (anti-IL-33), and REGN3767 (anti-LAG-3) were discovered and initially developed under this Antibody Discovery Agreement. Praluent®, Dupixent®, Kevzara®, and REGN3500 will continue to be developed, and commercialized as applicable, with Sanofi under the Antibody License and Collaboration Agreement. The first agreement was conclused in November 2011 to develop an anti IL6R antibody and an anti Delta-like Ligand 4 (Dll4) antibody. The agreement have been expanded in 2009 with the goal to advance 4 to 5 antibodies per year into clinical development.
- In July 2015, Sanofi and Regeneron Pharmaceuticals have entered into a new global collaboration in immuno-oncology. REGN2810 and REGN3767 will continue to be developed with Sanofi under this collaboration.
- Upon expiration of the Antibody Discovery Agreement, Regeneron has the right to develop or continue to develop other product candidates discovered under this agreement independently or with other collaborators. The $130 million of 2017 annual funding from Sanofi under the Antibody Discovery Agreement is expected to be fully utilized by the end of the third quarter of 2017.
Financial terms:
Latest news:
Is general: Yes
